MP70-16 COMPARISON OF OVERALL SURVIVAL BETWEEN THE LIFE EXPECTANCY AND THE ACTUAL ESTIMATED OUTCOME IN PATIENTS WHO RECEIVED PRIMARY ANDROGEN DEPRIVATION THERAPY

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced II1 Apr 2014MP70-16 COMPARISON OF OVERALL SURVIVAL BETWEEN THE LIFE EXPECTANCY AND THE ACTUAL ESTIMATED OUTCOME IN PATIENTS WHO RECEIVED PRIMARY ANDROGEN DEPRIVATION THERAPY Nobumichi Tanaka, Hinotsu Shiro, Hideyuki Akaza, Yoshihiko Hirao, and Kiyohide Fujimoto Nobumichi TanakaNobumichi Tanaka More articles by this author , Hinotsu ShiroHinotsu Shiro More articles by this author , Hideyuki AkazaHideyuki Akaza More articles by this author , Yoshihiko HiraoYoshihiko Hirao More articles by this author , and Kiyohide FujimotoKiyohide Fujimoto More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2214AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To compare overall survival between the life expectancy and the actual estimated outcome in patients who received primary androgen deprivation therapy. METHODS Out of 19250 patients who received androgen deprivation therapy between 2001 and 2003 in the Japan Study Group of Prostate Cancer (J-CaP Study Group; http://www.j-cap.net), a total of 15265 patients with whole clinical data set including age, PSA value, Gleason score, clinical stage and co-morbidity was enrolled in this retrospective study. The median age, PSA value at diagnosis, and follow-up period were 75 years (range: 35-99), 5.0 ng/mL (range: 0.01-30789), and 36 months (range: 1-147), respectively. The clinical TNM classification was followed by 1997 UICC classification. The proportion of low risk, intermediate risk, high risk, very high risk (cT3a-bN0M0), locally advanced (T4 or N1), and Metastatic (M1), were 11.5%, 12.2%, 24.1%, 19.1%, 6.1%, and 26.6%, respectively. The life expectancy was defined by using a simple life table of Japanese. Patient whose life expectancy at diagnosis is longer than the follow-up period is defined as □galive□h at last follow-up day. Patient whose life expectancy at surgery is shorter than the follow-up period is defined as □gdeath□h with survival time as same as the life expectancy. The overall survival was estimated by Kaplan-Meier method. The difference was tested by log-rank test. RESULTS The estimated 5-year and 10-year overall survival rate were 77.8%, and 61.5%, respectively. On the other hand, the 5-year and 10-year life expectancy were 98.4% and 76.1%, respectively. The actual estimated overall survival was significantly lower than the life expectancy (p<0.001). This trend was observed in all risk groups. The overall survival without cancer death was also significantly lower than the life expectancy not only in all patients but also in each risk group. There was no significant difference between the overall survival without cancer death and the life expectancy in the elderly patients (80 years or greater) (p=0.174). CONCLUSIONS The estimated overall survival was significantly lower than the life expectancy in patients who received primary androgen deprivation therapy. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e811-e812 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Nobumichi Tanaka More articles by this author Hinotsu Shiro More articles by this author Hideyuki Akaza More articles by this author Yoshihiko Hirao More articles by this author Kiyohide Fujimoto More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...